Trial Profile
Evaluation of the Efficacy and Safety of GS-5745 as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Subjects With Moderate to Severe Rheumatoid Arthritis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Andecaliximab (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms RA POC
- Sponsors Gilead Sciences
- 31 May 2018 Planned primary completion date changed from 1 Apr 2018 to 26 Jun 2017.
- 31 Aug 2017 The trial has been completed in Hungary (End date: 2017-08-07).
- 15 Aug 2017 Status changed from active, no longer recruiting to discontinued due to discontinuation of development for this indication.